Clinical Research
Filter News
Found 137,551 articles
-
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
8/3/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine, ReCOV from the Food and Drug Administration of the Philippines.
-
According to two recent studies, 10 to 30% of people with COVID-19 reported at least one persistent symptom up to six months after infection, which qualifies as Long COVID. -
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer. -
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
-
BioSpace sat down with Katy Powell, a psychiatric mental health nurse practitioner in Portland, Oregon, to discuss the relative risks and benefits associated with psychedelic-assisted therapy.
-
The FDA has placed a clinical hold on Beam Therapeutics' leukemia/lymphoma therapy and has lifted the hold on Celyad's CAR-T candidate for colorectal cancer. -
Eliem Therapeutics Provides ETX-810 Program Update
8/2/2022
Eliem Therapeutics , Inc. today reported results from its Phase 2a clinical trial investigating ETX-810 for the treatment of lumbosacral radicular pain (LSRP).
-
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) Topline Pivotal trial results expected 1H2023
8/2/2022
Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803.
-
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
8/2/2022
Avidity Biosciences, Inc. today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).
-
Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.
8/2/2022
Orca Bio today announced Precision-T, its pivotal Phase 3 study, is open.
-
Eleven Therapeutics Announces $22 Million in Seed Funding
8/2/2022
Eleven Therapeutics announced today that it has raised a total of $22 million in seed funding.
-
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America
8/2/2022
Acurx Pharmaceuticals, Inc. announced today that new microbiome data from its Phase 2a clinical trial (completed in 4Q 2020) in patients with C. difficile Infection (CDI) were presented at the 16th Biennial Congress of the Anaerobe Society of America.
-
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseTop-line data from all subjects expected by the first quarter of 2023
8/2/2022
Caladrius Biosciences, Inc. announced today the completion of enrollment and dosing in its Phase 1b, open-label, proof-of-concept study of CLBS201, a CD34+ regenerative cell therapy investigational product for intra-renal artery administration, for the treatment of diabetic kidney disease.
-
Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
8/2/2022
Satsuma Pharmaceuticals, Inc . today announced completion of subject enrollment in the Company’s ongoing STS101 SUMMIT pivotal Phase 3 efficacy trial, with more than 1,400 subjects randomized. Satsuma expects to announce topline results from the SUMMIT trial in the fourth quarter of 2022.
-
Diadem Presents Data at 2022 Alzheimer's Association International Conference® Showing Its Blood-Based Biomarker Test Can Both Diagnose and Predict Alzheimer's Disease
8/2/2022
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), today reported that study data presented at the Alzheimer's Association International Conference® 2022 (AAIC®) in San Diego.
-
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
8/2/2022
Salarius Pharmaceuticals, Inc. and VolitionRx Limited today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage drug, seclidemstat.
-
InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
8/2/2022
InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas.
-
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
8/2/2022
Halozyme Therapeutics, Inc. announced that Roche's Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® with Halozyme's ENHANZE® technology met its co-primary endpoints.
-
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
8/2/2022
Lucid Diagnostics Inc. today announced that LucidDx Labs Inc. (“LucidDx Labs”), has entered into participating provider agreements with preferred provider organizations Prime Healthcare, Three Rivers Provider Network, and Galaxy Health Network (the “PPOs”), as well as Alivio Health, a specialized diagnostic laboratory network.
-
Twist Bioscience Highlights White Paper Sizing Future DNA Data Storage Market
8/2/2022
Twist Bioscience Corporation today shared a new white paper from Furthur Market Research1 highlighting the dramatic need for new enterprise storage technologies that can be deployed more cost effectively at massive scale with minimal power consumption, such as DNA data storage.